Skip to content

Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis

AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01528813
Enrollment
30
Registered
2012-02-08
Start date
2012-02-29
Completion date
2013-12-31
Last updated
2013-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Onychomycosis

Keywords

Erbium-doped yttrium aluminium garnet laser, Er:YAG, Amorolfine lacquer, Dermatophytes, Subungual distal lateral onychomycosis, Drug delivery

Brief summary

The study aims to investigate the effectiveness of a single application of Er:YAG laser to the nail plate in increasing the efficacy of the amorolfine lacquer used in the treatment of onychomycosis (fungal infection of nails) cause by dermatophyte molds. This clinical trial respective involve 30 subjects with hands or feet distal-lateral subungual onychomycosis (a kind of onychomycosis that does not affect the ungual matrix). The patients will receive treatment for 6 months meanwhile they will be followed up to access efficacy of the treatment by means of the clearance of nail plate infection.

Detailed description

This is a trial study involving 30 subjects with onychomycosis of hands or feet. The patient must have at least 2 injured nails as each affected nail will receive a different treatment - self-controlled study design. Therefore, each nail out of two from a single patient will be randomized into the following study arms: Group A of nails - will receive only weekly application of amorolfine lacquer for a total of 6 months. Group B of nails - will receive a single application of Er:YAG laser followed by weekly application of amorolfine lacquer for a total of 6 months. At the end of 6 months the data from both groups, A and B, regarding \*clinical cure, \*mycological cure and \*extent of damage to the nail plates will be analyzed using specific tests.

Interventions

DEVICEEr:YAG laser + amorolfine lacquer

To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.

DRUGAmorolfine lacquer

To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.

Sponsors

Brasilia University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* 19-60 year-old * preserved cognitive status * direct mycological examination or culture showing infection of hands or feet nails by dermatophyte molds

Exclusion criteria

* diabetes type 1 or 2; peripheral vascular disease * having undergone any treatment in the last 6 months * peripheral nerve disorders (e.g. peripheral neuropathy, Hansen's disease, etc) * willing to paint nail during the study * high blood pressure * use of any immunosuppressive drugs; congenital or acquired immunodeficiency

Design outcomes

Primary

MeasureTime frameDescription
Extent of nail plate damage6 monthsAt the beginning and after 6 months of treatment both the group, A and B, will have the length from nail cuticle to the closest point of damage to the nail plate measured by a millimeter scale. It will later be accessed to determine the clearance rate of the nail plate achieved with each treatment

Secondary

MeasureTime frameDescription
Mycological cure6 monthsAfter 6 months of treatment both the group, A and B, will be accessed by direct mycological examination and culture to evaluate mycological cure
Clinical cure6 monthsAfter 6 months of treatment both the group, A and B, will be accessed by dermatological examination to evaluate clinical cure

Countries

Brazil

Contacts

Primary ContactOrlando O Morais, Investigator
orlando.unb@gmail.com+55(61)9916-2339

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026